Yes, there are documented cases of NAD⁺ supplementation causing adverse effects such as flushing, gastrointestinal distress, and altered liver enzyme levels in clinical studies—though these effects vary significantly by precursor compound.
Flushing is most commonly associated with nicotinic acid (niacin), while gastrointestinal distress and liver enzyme alterations are primarily reported with high-dose nicotinamide and, to a lesser extent, other precursors. However, the newer NAD⁺ precursors—nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN)—have demonstrated favorable safety profiles in clinical trials, with no significant increases in liver enzymes and only mild, transient gastrointestinal side effects [2, 3, 12]. In fact, several studies suggest that NR and NMN may improve liver function rather than impair it, particularly in individuals with metabolic conditions like non-alcoholic fatty liver disease (NAFLD) [2, 3]. Thus, while adverse effects are documented, they are not universal and are largely dependent on the specific precursor, dose, and individual susceptibility.
What the AI assistants say
AI assistants collectively emphasize that flushing, gastrointestinal distress, and liver enzyme alterations are documented adverse effects of NAD⁺ precursor supplementation. They agree that flushing is primarily linked to nicotinic acid (niacin) due to activation of the GPR109A receptor, leading to prostaglandin release and vasodilation [1]. This effect is dose-dependent, occurring even at 50 mg/day and becoming nearly universal at doses exceeding 500 mg/day [1]. The assistants also note that gastrointestinal symptoms—such as nausea, diarrhea, and abdominal pain—are reported with niacin and nicotinamide, particularly at high doses, though they are generally less severe than flushing [1]. Regarding liver enzyme changes, AI assistants highlight that sustained-release niacin formulations are associated with a higher risk of hepatotoxicity, with elevated ALT and AST levels reported at doses exceeding 2,000–3,000 mg/day, especially with long-term use [1]. They acknowledge that NR and NMN are generally better tolerated, with minimal flushing and no significant liver enzyme elevation in most studies [1]. However, they do not consistently distinguish between the effects of different formulations or highlight the potential for NR and NMN to improve liver function, which is a key divergence from the research corpus.
What the research actually shows
Flushing is a well-documented adverse effect, but it is almost exclusively linked to nicotinic acid (niacin). This response results from activation of the G-protein-coupled receptor GPR109A on immune and vascular cells, triggering prostaglandin D2 (PGD2) and E2 (PGE2) release, which causes cutaneous vasodilation and flushing [12]. In human studies, even 100 mg/day of niacin has been shown to increase lymphocyte NAD⁺ concentrations fivefold, but this is often accompanied by flushing [12]. Higher doses (1–3 g/day), used in lipid-lowering therapy, cause significant flushing, which can be mitigated with aspirin or extended-release formulations [12]. In contrast, nicotinamide (NAM), NR, and NMN do not activate GPR109A and thus do not typically cause flushing [2, 3]. This distinction is critical: flushing is not a general feature of NAD⁺ supplementation but is specific to niacin.
Gastrointestinal (GI) distress—such as nausea, diarrhea, and abdominal discomfort—is reported with nicotinamide and, less frequently, with NR and NMN. However, these effects are generally mild and transient. In a 2021 trial of NMN in prediabetic women, no significant GI issues were reported, suggesting good tolerability at doses used [2]. Similarly, a 6-month trial of NR plus pterostilbene in patients with NAFLD reported no major adverse events, though some participants experienced mild GI discomfort [2, 3]. In a study on NR in healthy older adults, the most common adverse events were mild GI symptoms, but they were not severe enough to cause discontinuation [2]. These findings indicate that GI distress is dose-dependent and more likely with higher doses or specific formulations, but it is not a major barrier to long-term use for NR and NMN.
Regarding liver enzyme alterations, the research shows a nuanced picture. While high-dose nicotinamide (≥1,500 mg/day) has been linked to elevated liver enzymes in rare case reports, this is not common and appears to be more relevant in individuals with pre-existing liver conditions [12]. In contrast, NR and NMN have shown no increase in liver enzymes and, in some cases, actual improvement. A 6-month trial of NR plus pterostilbene in patients with NAFLD found reduced levels of ALT, AST, and other liver enzymes, indicating improved liver function [2, 3]. Similarly, a trial of MIB-626 (a polymorph of NMN) in overweight or obese adults reported no increase in liver enzymes and instead observed reductions in markers of liver dysfunction [2, 3]. These findings suggest that NMN and NR may not only be safe for the liver but may even support its health, especially in metabolic contexts [2, 3]. This is a critical point of divergence: while AI assistants note the possibility of liver enzyme changes, they do not highlight that NR and NMN may improve liver function, a finding supported by multiple clinical trials [2, 3]. In contrast, metformin—often discussed alongside NAD⁺ boosters—has been associated with liver enzyme abnormalities in rare cases, particularly in individuals with pre-existing liver disease [14, 15], but this is unrelated to NAD⁺ supplementation itself.
Where the AI consensus and the research diverge
The AI assistants correctly identify flushing as a major adverse effect of niacin and note GI distress and liver enzyme changes with high-dose nicotinamide. However, they fail to emphasize that NR and NMN—two of the most commonly studied NAD⁺ precursors—do not cause flushing and are associated with no increase in liver enzymes. More importantly, the research corpus reveals that these compounds may actually improve liver function in metabolic conditions, a benefit not reflected in the AI summaries. This divergence underscores a critical point: adverse effects are not inherent to all NAD⁺ supplementation but are highly compound-specific. The AI assistants present a more generalized risk profile, while the research shows that modern precursors like NR and NMN are well-tolerated and potentially hepatoprotective.
Bottom line: While flushing and rare liver enzyme changes are documented with niacin and high-dose nicotinamide, NR and NMN have demonstrated excellent safety in clinical trials, with no significant adverse effects and even evidence of improved liver function [2, 3, 12].
References
- Boundless Upgrade Your Brain, Optimize Your Body and Defy — Ben Greenfield
- Current Topics in Cellular Regulation
- High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity
- Human trials exploring anti-aging medicines — Guarente, Leonard (author)
- NAD⁺ in aging, metabolism, and neurodegeneration
- NAD⁺ metabolism and the control of energy homeostasis – a balancing act between mitochondria and the nucleus
- Protective effects of sirtuins in cardiovascular diseases — Stephan Winnik
- Studies on relaxation of rabbit aorta by sodium nitrite_ the basis for the proposal that the acid-activatable inhibitory
Continue your research
Part of our NAD+: Safety, Side Effects & Regulation guide.
- What are the long-term safety profiles of high-dose NAD+ supplementation, including potential impacts on liver function, immune modulation, and cancer risk?
- Is there evidence that NAD+ supplementation can exacerbate pre-existing conditions such as cancer or autoimmune disorders, particularly in high-dose regimens?
- Are there any known drug interactions between NAD+ precursors and medications such as statins, anticoagulants, or chemotherapy agents?
Related topics:
- How do age and baseline NAD+ levels influence the dose-response relationship for NMN and NR supplementation in clinical trials?
- What are the documented long-term benefits of NAD+ supplementation in improving mitochondrial function and reducing age-related decline in physical and cognitive performance?
- What is the current state of clinical evidence supporting NAD+ supplementation for age-related decline, and how do randomized controlled trials compare to preclinical models in demonstrating efficacy?